Thermo Fisher Scientific is making a bold move to revolutionize Asia's biopharma landscape! But is it enough to meet the region's soaring demands?
Thermo Fisher Scientific, the global leader in scientific solutions, is intensifying its presence in Asia's biopharma sector with a strategic expansion. On December 2, 2025, the company announced the growth of its bioprocessing capabilities, establishing a new Bioprocess Design Center in Hyderabad, India, and expanding existing centers in Incheon, Korea, and Singapore. This expansion aims to provide local expertise, cutting-edge technologies, and customized support to biopharma pioneers across Asia.
The Asian biopharma market is booming, driven by the rising demand for biologics, vaccines, and cell and gene therapies. Thermo Fisher's increased investment in the region is a direct response to this growth, offering customers access to top-tier technologies, expertise, and localized support to expedite the development of groundbreaking therapies.
"Asia is a pivotal player in the global biopharma innovation arena," stated Daniella Cramp, Senior Vice President and President of BioProduction at Thermo Fisher Scientific. "By extending our reach in Korea, Singapore, and India, we're bringing our exceptional infrastructure and expertise right to our customers' doorsteps, enabling them to produce high-quality biologics more swiftly, economically, and sustainably."
Here's where Thermo Fisher's strategy gets intriguing:
- Incheon, Korea: The expanded Bioprocess Design Center fosters enhanced collaboration and innovation through cutting-edge materials, technologies, and upgraded lab facilities.
- Hyderabad, India (Genome Valley): This new center, a joint venture with the Government of Telangana, provides collaborative spaces for process design, simulation, and optimization. It empowers customers to co-create and test bioprocesses using state-of-the-art single-use and hybrid systems, propelling India's burgeoning biomanufacturing sector.
- Singapore: The expanded facility offers bench-to-pilot scale bioprocessing, expert training, and deep collaborations with Thermo Fisher's technical teams, enabling the scaling of early-stage processes for flexible and sustainable biomanufacturing.
These centers collectively ensure customers have immediate access to innovation, training, and technical expertise, fostering agility, scalability, and quicker market entry for biologics production.
Thermo Fisher's impact extends beyond infrastructure. The company delivers groundbreaking technologies in next-generation sequencing, mass spectrometry, and advanced bioprocessing systems. Its comprehensive capabilities, spanning life sciences, diagnostics, analytical instruments, and pharma services, empower customers across the entire biopharma value chain.
"We're reshaping the boundaries of biologics production through advanced manufacturing, strategic alliances, and targeted regional investments," said Tony Acciarito, President of Asia Pacific and Middle East, Africa at Thermo Fisher Scientific. "We take pride in our role in Asia's biopharma evolution and are dedicated to assisting our customers in delivering life-altering therapies to patients across Asia and the world."
Controversy Alert: Some argue that such large-scale investments in Asia's biopharma sector could potentially lead to a brain drain from other regions. Is this a valid concern, or is it a necessary step to meet the global demand for biopharma innovations? Share your thoughts below!
To explore Thermo Fisher's Bioprocess Design Centers, visit www.thermofisher.com/bdc. Learn more about Thermo Fisher Scientific, a company with over $40 billion in annual revenue and a mission to support customers in making the world healthier, cleaner, and safer, at www.thermofisher.com.
